Articles

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia

Department of Leukemia
Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston
Department of Leukemia
Department of Leukemia
Department of Leukemia
Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston
Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston
Ono Pharmaceutical Co. Ltd., Research Center of Oncology, Osaka
Ono Pharmaceutical Co. Ltd., Research Center of Oncology, Osaka
Department of Leukemia
Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston
Department of Leukemia
Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston
Department of Leukemia
Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston
Department of Leukemia; Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston
Haematologica Early view Nov 4, 2021 https://doi.org/10.3324/haematol.2021.278369